In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…
In a new collaboration, the Computational Health Center at Helmholtz Munich has teamed up with the global pharmaceutical company Pfizer. The joint initiative, spanning three years, aims to leverage Pfizer's vast knowledge and accumulated data in…
Helmholtz Munich is bringing together a wide range of experts to advance the development of foundation models focused on health research. The Munich Health Foundation Model Symposium, to be held on April 10, 2024, at the Helmholtz Munich Campus, aims…
EU Project PerForM-REACT Strengthens Pandemic Preparedness Efforts
On March 11, 2024, the inauguration of the expanded safety laboratory in Augsburg marked a milestone within the EU-funded "PerForM-REACT" project, aimed at enhancing pandemic…
TherVacB, a novel therapeutic vaccine to combat chronic hepatitis B, entered the first clinical trial. The vaccine was designed and developed under the leadership of Helmholtz Munich. This phase 1a clinical trial is conducted at the Division of…
2023 has changed the way we treat obesity. A new class of drugs, mimicking a gut hormone called glucagon-like peptide-1 (GLP-1), is reshaping medicine and improving many people’s lives globally. GLP-1 drugs do not only induce significant weight loss,…
We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here: